PARTNERSHIPS

Driving science and medicine forward, together

Paretor Partners

Paretor is a manufacturer, not a pharmaceutical company. We work with academia, biotech founders, manufacturers, and other industry partners to develop nanoparticle colloids for non membrane-disruptive delivery of small molecules, nucleotides, peptides, and other cargo to the cell cytoplasm.

If you are interested in custom particle synthesis or would like to talk about how Paretor iron oxide nanoparticle colloids could be used in your research, please reach out!

WHAT MAKES PARETOR DIFFERENT

Paretor is a manufacturer, not a pharmaceutical company. Particles + novel cargo can be licensed and patented for development.

We offer product-associated services such as custom particle services and particle validation.

Particles are R & D ready and GMP-enabled.

[01]

ETAERION

Cell Viability and Stability

ETAERION (PA-002) is a magnesium-integrated mineral nanoparticle colloid that stabilizes cellular systems under stress. It is designed to be used in research and commercial settings to improve stability and viability of cell lines and organoid systems. Contact us for wholesale purchase.

ETAERION for research can be purchased here.

Product data can be found here.

Our partners include:

Drug manufacturers

Research laboratories

Businesses which rely on cell stability and viability

[02]

Delivery

Paretor nanoparticle colloid PA-001 can be used for non-disruptive RNA delivery to the cell cytoplasm and are adapted for siRNA screening. Paretor is looking for academic and industry partners who are interested in delivering RNA outside of the liver.

Paretor nanoparticle colloid PA-001 can also be modified with small molecules, peptides, and other cargo for delivery to the cell cytoplasm. Delivery into the cytoplasm paves the way for low-dose delivery, novel therapeutics, and true reformulation of existing agents. Contact us to learn about bespoke particle synthesis.

Product data can be found here.

Our partners include:

Academic and commercial research labs involved in drug delivery

Research labs involved in siRNA screening

Pharmaceutical companies reformulating existing drugs

Pharmaceutical companies rescuing/repurposing orphan drugs

Biotech interested in delivery of novel actives to the cell cytoplasm